Botulinum Toxin for Pediatric Migraine: A Retrospective Multisite Cohort Study.

Area of Science:

• Neurology
• Pharmacology

Background:

• Efficacy of Onabotulinum toxin A for chronic migraine is established in adults but not well-defined in adolescents.
• Adolescent chronic migraine presents unique challenges in treatment efficacy and safety.

Purpose of the Study:

• To evaluate the safety and efficacy of Onabotulinum toxin A and Incobotulinum toxin A in adolescent patients with chronic migraine.
• To compare treatment outcomes with existing studies in adult populations.

Main Methods:

• Retrospective chart review of 51 adolescents receiving Onabotulinum toxin A or Incobotulinum toxin A for headache prevention.
• Data collected included demographics, headache characteristics, and treatment outcomes.
• Primary endpoint: 50% reduction in headache frequency; secondary endpoints: reduction in headache days, repeat injections, use of other migraine medications, and adverse events.

Main Results:

• 69% of adolescents achieved a 50% reduction in headache days within 16.6 weeks of initial injection.
• Average reduction of 13.1 headache days per month observed.
• Low incidence of adverse events (4%), primarily neck soreness and headache post-injection.

Conclusions:

• Onabotulinum toxin A and Incobotulinum toxin A show significant efficacy in reducing headache frequency for adolescents with chronic migraine.
• Treatment is well-tolerated, with a low rate of adverse events in this population.
• Results suggest botulinum toxin therapy may be more effective in adolescents than previously reported in other studies.